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Abstract
AIM: To compare the efficiency of different plasmids as
DNA vectors by cloning three HBsAg-encoded genes into
two eukaryotic expression vectors, pRc/CMV and pSG5UTPL/
Flag, and to express HBsAg S, MS, and LS proteins in SP2/
0 cells, and to establish monoclone SP2/0 cell strains that
are capable of expressing S or S2S proteins stably.
METHODS: Segments of S, preS2-S, preS1-preS2-S genes
of Hepatitis B virus were amplified by routine PCR and preS1-
S fragment was amplified by Over-Lap Extension PCR. The
amplified segments were cleaved with restricted
endonuclease Hind III/Not I followed by ligation with pRc/
CMV, or BamHI/EcoR I followed by ligation with pSG5UTPL/
Flag. After the plasmid vectors were cleaved with the
correspond enzymes, the amplified segments were inserted
into pRc/CMV or pSG5UTPL/Flag plasmid vectors with T4
DNA ligase. KOZAK sequence was added before the initial
ATG code of each fragment using specific primer. The
inserted segments in the recombinant plasmids were
sequenced after subcloning. BALB/c mice myeloma cells
(SP2/0 cell line) were transfected with the recombinant
plasmids. The expressions of the different recombinants were
Compared by Western-blot, using a monoclonal anti-HBs
antibody as the primary antibody and peroxidase-labeled
multi-linker as the secondary. Stable SP2/0-pRc/CMV-S or
SP2/0- pRc/CMV-MS clones were established through clone
screening with G418.
RESULTS: Fragments with anticipated size were harvested
after PCR. After recombination and screening, the sequences
of the inserted segments in the recombinants were confirmed
to be S, preS2S, preS1-preS2S and preS1S encoding genes,
determined by sequencing. The results of Western-blot
hybridization were positive for the anticipated proteins.
Among them, pRc/CMV-S or pRc/CMV-MS demonstrated the
highest expressing their respective antigen.
CONCLUSION: Eight recombinant plasmids expressing S,
M, L or preS1S proteins are obtained. For hepatitis surface
antigen expression in eukaryotic cells, the vector pRc/CMV
is superior to pSG5UTPL/Flag, and pRc/CMV-S and pRc/CMV-
MS are the most efficient in the pRc/CMV clones. SP2/0
cells stably expressing HBsAg are established, and may be
used as target cells for evaluating the CTL activity of a DNA
vaccine in vitro.
Qin S, Tang H, Zhao LS, Lin Y, Liu L, He XM. Cloning of
HBsAg-encoded genes in different vectors and their
expression in eukaryotic cells. World J Gastroenterol  2003;
9(5): 1111-1113
http://www.wjgnet.com/1007-9327/9/1111.htm
INTRODUCTION
Hepatitis B virus (HBV) infection is epidemic worldwide[1-3].
Unfortunately, there are no satisfactory drugs to cure HBV-
related diseases, and the only way to control the epidemic is
through vaccination[4-6]. Great efforts have been made to
develop more successful vaccines than those currently available
to prevent or to treat HBV infection. The newest approach is
genetic immunization. This involves the transfer of a viral gene
into host somatic cells by a plasmid vector, with subsequent
endogenous production and intracellular processing of the
virus’ structural proteins into small peptides. The processed
peptides eventually induce a broad-based immune response[7-11].
Hepatitis B virus surface antigen consists of S (S, small surface),
MS (medium surface, S+preS2), and LS (large surface,
S+preS1+preS2) HBsAg molecules. We have reported that DNA
vaccine expressing HBsAg S molecule induced humoral and
cellular immune responses against HBsAg[12,13]. Because the
preS antigen is necessary for HBV to penetrate the cell
membrane of the host, vaccines containing the preS antigen
are more effective. Hence, we constructed a series of plasmids
encoding small (S), medium (M), or large (L) envelope proteins
of HBsAg utilizing different promoters. In addition, the
expression levels of these recombinant plasmids were
evaluated, in order to choose a better vector for designing future
DNA vaccines.
MATERIALS AND METHODS
Gene fragments expressing S, MS, LS, and preS1S proteins
Plasmid pBHB4 (containing the adr subtype of HBV genome
DNA) was used as a template to amplify S, preS2 and preS1
fragments. The following primers were used: the forward
primers: SF (nt 28-41), 5’- GCG AAT TCT AGC TTA TCG
ATC ACC ATG GAG AAC ACA AC, complementary to the S
gene; S2F (nt 3077-3090), 5’- GCG AAT TCA AGC TTA TCG
ATC ACC ATG CAG TGG AAC ACA TC, complementary to
the preS2 gene; and S1F (nt 2179-2733), 5’- GCG AAT TCA
AGC TTA TCG ATC ACC ATG GGA GGT TGG TC,
complementary to the preS1 gene. The same reverse primer
was used for all reactions: SR (nt 705-693): GCG CGG CCG
CTT AGG ATC CAA TCG ATA CCC AA. The primers contain
a flanking sequence having endonuclease enzyme sequence
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for the convenience of clone manipulation.
     To obtain a unique fragment containing the S and preS1
gene, overlap extension PCR was used. The forward primer
(S1-SF) is complementary to the beginning of the S gene and
to the end of preS1 gene, while the reverse primer (S-S1R) is
complementary to the end of the preS1 gene and the beginning
of the S gene (Figure 1). Using pBHB4 as a template, and the
S1-SF/SR and S1F/S-S1R primers, the resultant PCR product
contained the 3’ end of preS1 gene followed by the complete S
gene sequences that the two PCR fragments contained
complementary ends. When these fragments were consequently
used as templates and S1F/SR primers, only the preS1-S was
amplified.
S1-SF (5’)        CAT CCT CAG GCC  ATG GAG AAC ACA
                         preS1 (nt3065-3076)            S(nt28-39)
S-S1R (5’)       TGT GTT CTC CAT  GGC CTG AGG ATG
                                S(nt39-28)            preS1(nt3076-3065)
Figure 1  Primers designed for Overlap-Extension PCR.
Recombinant plasmids construction
The PCR fragments and plasmid vector pRc/CMV (containing
the CMV promoter, Invitrogen, USA) were cleaved by HindIII/
NotI (Bio-Lab, USA), while the PCR fragments and plasmid
vector pSG5UTPL/Flag (containing SV40 promoter) were
cleaved by BamHI/EcoR I (Bio-Lab, USA). The cleaved
products were ligated using T4 DNA ligase. E.coli XLBlue1
was transformed using the ligated products and screened for
the positive clones containing the inserted fragments, which
was performed by colony-PCR techniques. The positive
colonies were amplified, extracted, purified, and identified by
endo-nuclease cleavage. The sequences of the inserted
fragments were confirmed by sequencing with Nucleic Acid
Auto-Analysis (TYPE 373A).
Transient expression in vitro
The extracted recombinant plasmids were purified by CsCl/
ethidium bromide equilibrium centrifugation. SP2/0 cells
(myeloma cells from inbred BALB/c mice) were transfected
with purified plasmids by an amended calcium chloride
method as described elsewhere[14]. Two days later, the cells
were collected in LAC buffer (20 mmol·L-1 Hepes pH 7.9,
400 mmol·L-1 NaCl, 1 mmol·L-1 EDTA, 9 mmol·L-1 CHAPS,
250 ml·L-1 glycerol) containing 1/200V 0.5 mol·L-1 DTT,
2.5 mmol·L-1 EDTA, 5 g·L-1 Apotinine, 5 g·L-1 Leupetine and
0.2 mol·L-1 PMSF, and lysed by sonication (Ubra-Cell, Sonics
& Materials, USA). Supernatants were collected and analyzed
as follows: proteins were separated by 120 g·L-1 SDS-
polyacrylamide gel, electrophoresis, and transferred to PVDF
membranes (Millipore, USA), followed by blocking for 2 h in
PBS containing 50 g·L-1 nonfat dry-milk at room temperature.
To detect HBsAg, the membranes were first incubated with
mono-clone anti-HBs antibody (BioGenex, USA) at 1:1 000
dilution and conjugated antibodies were detected with
horseradish peroxidase-labeled multi-linker antibodies
(BioGenex, USA) at a dilution of 1:300. The blots were
visualized by chemiluminescence reactions (Luminol and
Iodophenol, Fluka).
Long-term transfected cell strains
After the transient in vitro expression, the plasmids
demonstrating a high level of expression were chosen to
permanently transfect SP2/0 cells. After 2 d of transfection,
fresh cultural medium containing 200 mg·L-1 G418 (at this
concentration, there were no viable SP2/0 cells after 2 w in
preliminary studies) was added in order to grow the cells under
G418 pressure. The media was refreshed every 3 to 5 d. 2w
later, cells forming colonies were chosen using a light
microscope, and subcultured under G418 pressure. After 30
generations, the DNA was extracted following the protocols
described elsewhere[15] and detected the HBV S gene by dot-
blot hybridization (Dig-probe of HBV S was prepared in our
laboratory, Dig-labeling Kit from Roche Company). HBsAg
in the culture media and supernatant of cell lyses were detected
by ELISA (Kits from SABC), HBsAg in the cells by
immunochemistry. Presence of the plasmid was detected by
in situ hybridization with the corresponding probe (labeled in
our laboratory, Dig-label kit from Roche Company). The cells
containing the HBV S gene and the HBsAg were chosen as
long-term expression cell strains and stored in liquid nitrogen
for further use as the target cells for evaluation of CTL activity
after DNA immunization.
RESULTS
Construction of recombinant plasmids
DNA fragments of 0.72kb, 0.88kb, and 1.24kb were generated
by PCR methods (pBHB4 template and SF/SR, S2F/SR, S1F/
SR primers). The length of these fragments corresponded to
the length of S, MS, and LS genes. When the PCR product
primed by S1F/S-S1R and S1-SF/SR was used as templates
(overlap extension PCR), a 1.02kb DNA fragment, equal to
the length of preS1S was obtained. After cleavage by Hind III/
Not I, S, MS, LS and preS1S genes were inserted into a multiple
cloning site downstream of the CMV promoter in pRc/CMV,
while the fragments cleaved by Bam HI/EcoR I were inserted
into multiple cloning site downstream of the SV40 promoter
in pSG5UTPL/Flag.  E.Coli. XLBlue1 cells were transformed
separately with the series 8 recombinant plasmids, and cultured
in LB containing ampicillin. PCR was performed on colonies,
and 0.72kb, 0.88kb, 1.24kb, and 1.02kb fragments were
obtained. When these PCR products were cleaved by restriction
enzymes Hind III/Not I (pRc/CMV as vector) or Bam HI/EcoRI
(pSG5UTPL/Flag as vector), the anticipated DNA bands were
obtained. We have constructed CMV promoter controlled
recombinant plasmids: pCMV-S, pCMV-MS, pCMV-LS,
pCMV-S1S; and SV40 promoter controlled recombinant
plasmids: pSG5Flag-S, pSG5Flag-MS, pSG5Flag-LS,
pSG5Flag-S1S. KOZAK sequences (CACC) were placed
before the initiation code of all recombinant plasmids to enhance
the efficiency of protein expression. The sequences of the
inserted fragments of all 8 plasmids were identical to HBV-S,
MS, LS and preS1S genes, confirmed by following sequencing.
Transient expression
After SP2/0 cells were transfected with recombinant plasmids
above, the supernatants of lysed cells were run on SDS-PAGE
and Western-Blot, all were positive for the anticipated bands,
while the SP2/0 cells not transfected with the recombinants
were negative for any HBsAg antigen. Among them, pRc/
CMV-S and pRc/CMV-S2S demonstrated the highest
expression.
Construction of long-term expression cell strains
pRc/CMV-S and pRc/CMV-S2S were used to transfect SP2/0
cells. The transfected cells grew in clusters under the selection
pressure of G418. After 2 mo, 10 strains of SP2/0-pRc/CMV-
S and 16 strains of SP2/0-pRc/CMV-S2S continued to grow
well in G418-containing medium, while SP2/0 cells not
transfected with recombinant plamid died within 2 wk. Of the
G418 resistant monoclone cells, 3 strains of SP2/0-pRc/CMV-
S and 4 strains of SP2/0-pRc/CMV-S2S were positive for
HBsAg in the supernatants of sonicated cells. The HBsAg was
detected by ELISA. They were also positive for the protein
bands when detected by Western-Blot. Cytosolic HBsAg was
detected by immunochemistry. The 7 cell strains above were
also positive for pRc/CMV-S or pRc/CMV-S2S when detected
by in situ hybridization.
DISCUSSION
DNA immunization involves the recombination of the genes
of interest with the selected eukaryotic expression plasmid/
vector and the transfer of the recombinant plasmid into muscle
or skin cells of the host, with a subsequent induction of specific
immune responses[16-20]. DNA immunization is attractive for
its advantages over traditional vaccines, and is discussed in
elsewhere[21-24]. We have  reported that HBV DNA vaccine NV-
HB/s could express HBsAg in muscle cells after injecting into
mouse muscle, followed by the induction of an immune
response, including the switchover of anti-HBs production in
peripheral blood[12,13].
      HBsAg-encoded genes include S, preS1, and preS2. All the
proteins expressed by these genes are antigenic. The elicited
response is strongest with preS1 and preS2. The titer of preS
antibody in rabbits immunized with preS protein is 400 times
greater than that of S antibody in rabbits immunized with S
protein. In addition, some mice are non-responsive to S protein
of HBV, which is determined by an allele of H2 gene. Vaccines
containing HBV preS1 and/or preS2 antigen may alter this
inherited non-responsive state, inducing anti-HBs in mice
which were previously immunized with vaccines only
containing S. Moreover,  preS proteins are necessary in order
for HBV to infect hepatocytes. preS1 protein can bind
hepatocytes specifically while preS2 can bind hepatocytes
through PHSA (polymerase human serum albumin). Because
of the importance of HBV preS proteins, we constructed
plasmids, which can be used for DNA vaccines containing the
preS1 and/or preS2 genes. Several plasmids were constructed
by different promoters in order to compare their expression
proficiency. All these recombinant plasmids demonstrated
expression in SP2/0 cells, while the vector pRc/CMV was the
most effective, with the highest expression demonstrated as
pRc/CMV-S and pRc/CMV-S2S.  pRc/CMV-S and pRc/CMV-
S2S may be used as good candidates for DNA immunization.
Their efficacy in inducing immune responses is still in
experimental process.
     Long-term expression cell strains transfected with pRc/
CMV-S or pRc/CMV-S2S were established in our experiment
through selection with G418 more than 30 generations. The
cell lines SP2/0-pRc/CMV-S and SP2/0-pRc/CMV-S2S can
express HBsAg S protein or S2S protein effectively and may
be used as target cells for CTL test in the study of DNA
immunization for HBV in the near future.
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